Symbols

FHTX

Foghorn·NASDAQ

--(--)

FHTX Profile

Foghorn Therapeutics Inc.

A developer of therapeutics for genetically determined dependencies within the chromatin regulatory system

Industry

Biological Technology

Established Date

Listing Date

10/23/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

106

Fiscal Year Ends

12-31

Website

foghorntx.com

Security Type

Common stock

Office address

99 Coolidge Avenue, Suite 500, Watertown, Massachusetts 02472

Business

Introduction

Foghorn Therapeutics Inc., was incorporated in October 2015 as a Delaware corporation. The company is a clinical-stage precision therapy biotechnology company that is the first to develop a new class of drugs that target chromatin regulation systems to correct abnormal gene expression. Its proprietary Gene Traffic Control platform enables integrated research and targeting of the system, and its R&D pipeline focuses on oncology with potential applications in other disease areas.